Life Sciences Opportunities in India & China: From Innovation to Commercialization
September 30, 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
January 9, 2026
Foley Viewpoints
New York Further Amends CPLR §2106, Broadening and Clarifying the Use of Affirmations in Lieu of Affidavits and Other Sworn Statements
The evolution of Section 2106 from a narrow, procedural shortcut into a comprehensive substitute for affidavits, verifications, and other sworn statements marks a significant modernization and streamlining of New York practice, with this new amendment reflecting the legislature’s intent to align more with federal practice while preserving New York’s own unique statutory requirements.
January 9, 2026
Labor & Employment Law Perspectives
Navigating Workplace AI When Federal, State Policies Clash
January 9, 2026
Foley Viewpoints